A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells

The RAF Inhibitor Paradox Revisited

(2012) Adrienne D. Cox et al.   CANCER CELL

Tumor Necrosis Factor Signaling Requires iRhom2 to Promote Trafficking and Activation of TACE

(2012) C. Adrain et al.   SCIENCE

iRhom2 Regulation of TACE Controls TNF-Mediated Protection Against Listeria and Responses to LPS

(2012) D. R. McIlwain et al.   SCIENCE

Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain

(2011) Inken Lorenzen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells

(2011) M. Cioffi et al.   CLINICAL CANCER RESEARCH

Development of sandwich ELISA for detection and quantification of human and murine a disintegrin and metalloproteinase17

(2011) Ahmad Trad et al.   JOURNAL OF IMMUNOLOGICAL METHODS

ADAM17 promotes glioma cell malignant phenotype

(2011) Xuguang Zheng et al.   MOLECULAR CARCINOGENESIS

ADAM17: a molecular switch to control inflammation and tissue regeneration

(2011) Jürgen Scheller et al.   TRENDS IN IMMUNOLOGY

A rapid and scalable method for selecting recombinant mouse monoclonal antibodies

(2010) Cecile Crosnier et al.   BMC BIOLOGY

ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation

(2010) Xuguang Zheng et al.   CANCER BIOLOGY & THERAPY

ADAM17 Regulates Epidermal Growth Factor Receptor Expression through the Activation of Notch1 in Non-Small Cell Lung Cancer

(2010) A. Baumgart et al.   CANCER RESEARCH

ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers

(2010) G. Sinnathamby et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer

(2010) Athena Chalaris et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice

(2010) Athena Chalaris et al.   JOURNAL OF EXPERIMENTAL MEDICINE

In vivo role of leukocyte ADAM17 in the inflammatory and host responses during E. coli -mediated peritonitis

(2010) Chunmei Long et al.   JOURNAL OF LEUKOCYTE BIOLOGY

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

(2010) Ralf Lutterbuese et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands

(2010) K. Brandl et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by γ-secretase

(2009) Athena Chalaris et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

ADAM17 as a Therapeutic Target in Multiple Diseases

(2009) Joaquin Arribas et al.   CURRENT PHARMACEUTICAL DESIGN

Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release

(2009) Maria Amann et al.   JOURNAL OF IMMUNOTHERAPY

Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA

(2009) Ralf Lutterbuese et al.   JOURNAL OF IMMUNOTHERAPY

Multiple Mechanisms Are Responsible for Transactivation of the Epidermal Growth Factor Receptor in Mammary Epithelial Cells

(2008) Karin D. Rodland et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE